Tania Jain, MBBS, discusses the current treatment options for graft-versus-host-disease, a known complication of allogeneic stem cell transplant, which is the only curative treatment option for patients with myelofibrosis.
Tania Jain, MBBS
Advertisement
Articles by Tania Jain, MBBS
Tania Jain, MBBS, discusses the role of ruxolitinib as treatment of graft-versus-host disease.
Advertisement
Latest Updated Articles
Treating GVHD in Patients with Myelofibrosis Following TransplantPublished: April 10th 2020 | Updated:
Evaluating the Role of Ruxolitinib as Treatment of Graft-Versus-Host DiseasePublished: February 20th 2020 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
